Categories | Factors | AR in EMM group | AR in LMM group |
---|
Tumor | T-stage | 78.19% | 20.19% | 43.85% | 3.68% |
N-stage | 67.25% | 49.11% |
Pre-EB | 2.81% | -18.04% |
Post-EB | 14.28% | 2.19% |
Patient | Sex | 26.07% | 18.50% | 39.97% | 6.11% |
Age | -11.17% | 0.36% |
Pre-NLR | 14.54% | 4.62% |
Pre-HB | 9.60% | 19.77% |
Pre-PLR | 3.74% | 9.57% |
Post-HB | -9.79% | 7.76% |
- Abbreviations: AR attributable risks, EMM early metachronous metastasis (metastasis within 2 years after treatment), LMM late metachronous metastasis (metastasis beyond 2 years after treatment), Pre-NLR neutrophil-to-lymphocyte ratio before treatment, Pre-HB hemoglobin before treatment, Pre-PLR platelet-to-lymphocyte ratio before treatment, Pre-EBV DNA Epstein-Barr virus DNA before treatment, Post-HB hemoglobin after chemoradiotherapy, Post-EBV DNA Epstein-Barr virus DNA after chemoradiotherapy